ASH 2021 | Updates in the treatment landscape of p53-mutated AML/MDS
Rory Shallis
• 12 Dec 2021
In this video, Rory Shallis, MD, Yale Cancer Center, West Haven, CT, gives an overview on the treatment landscape of p53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Dr Shallis discusses the poor outcomes associated with this mutated form of AML/MDS, and how there has been little improvement in achieving long-term survival in patients. Dr Shallis then mentions some of the promising data from novel therapies, including APR-246, anti-CD47 therapies, and triplet therapy with magrolimab, azacitidine and venetoclax, and how these should prompt further research. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
